JP2022545167A5 - - Google Patents
Info
- Publication number
- JP2022545167A5 JP2022545167A5 JP2022505440A JP2022505440A JP2022545167A5 JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5 JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022505440 A JP2022505440 A JP 2022505440A JP 2022545167 A5 JP2022545167 A5 JP 2022545167A5
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- receptor
- chimeric cytokine
- cytokine receptor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962894658P | 2019-08-30 | 2019-08-30 | |
| US62/894,658 | 2019-08-30 | ||
| US202063053322P | 2020-07-17 | 2020-07-17 | |
| US63/053,322 | 2020-07-17 | ||
| PCT/US2020/048402 WO2021041806A1 (en) | 2019-08-30 | 2020-08-28 | Chimeric cytokine receptors comprising tgf beta binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022545167A JP2022545167A (ja) | 2022-10-26 |
| JP2022545167A5 true JP2022545167A5 (https=) | 2023-09-01 |
Family
ID=72521701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505440A Pending JP2022545167A (ja) | 2019-08-30 | 2020-08-28 | Ｔｇｆベータ結合ドメインを含むキメラサイトカイン受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12528856B2 (https=) |
| EP (1) | EP4021582A1 (https=) |
| JP (1) | JP2022545167A (https=) |
| KR (1) | KR20220052919A (https=) |
| CN (1) | CN114341193A (https=) |
| AU (1) | AU2020336131B2 (https=) |
| BR (1) | BR112022003553A2 (https=) |
| CA (1) | CA3145614A1 (https=) |
| IL (1) | IL290960A (https=) |
| MX (1) | MX2022002297A (https=) |
| WO (1) | WO2021041806A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021312871A1 (en) | 2020-07-21 | 2023-02-09 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| JP2024515181A (ja) * | 2021-04-19 | 2024-04-05 | ナンジン レジェンド バイオテック カンパニー，リミテッド | キメラサイトカイン受容体及びその細胞療法における使用 |
| AU2022335237A1 (en) | 2021-08-27 | 2024-03-28 | Theranotics Co., Ltd. | Bispecific molecule specifically binding to b7-h3 and tgfβ and uses thereof |
| CN115873802A (zh) * | 2021-09-29 | 2023-03-31 | 亘喜生物科技（上海）有限公司 | 嵌合抗原受体免疫细胞及其制法和应用 |
| EP4408873A1 (en) * | 2021-09-29 | 2024-08-07 | Vita Therapeutics, Inc. | Methods and compositions for treating cancer with engineered cells |
| AU2022371471A1 (en) * | 2021-10-20 | 2024-05-02 | Fate Therapeutics, Inc. | Effector cells and use thereof for allogeneic adoptive cell therapies in solid tumors |
| GB202117298D0 (en) * | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| CN118922196A (zh) * | 2022-02-18 | 2024-11-08 | 加利福尼亚大学董事会 | 嵌合细胞因子受体促进原代人nk细胞扩增和功能 |
| EP4499680A1 (en) | 2022-03-29 | 2025-02-05 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
| GB202301421D0 (en) * | 2023-02-01 | 2023-03-15 | Univ Oslo Hf | Switch receptor for use in adoptive cell therapy |
| CN116284449B (zh) * | 2023-02-27 | 2024-11-19 | 深圳市先康达生命科学有限公司 | 增强型TGF-βR嵌合受体及其应用 |
| CN121240874A (zh) * | 2023-06-06 | 2025-12-30 | 豪夫迈·罗氏有限公司 | 开关受体 |
| CN121532650A (zh) | 2023-06-20 | 2026-02-13 | 艾洛基治疗公司 | 工程化的细胞的检测方法 |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| AU3668897A (en) | 1996-07-17 | 1998-02-09 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| JP3499528B2 (ja) | 1997-11-26 | 2004-02-23 | 中外製薬株式会社 | シグナルシーケンストラップ法 |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| CA2738031C (en) | 2008-09-22 | 2022-11-29 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| CA2832569A1 (en) | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| US10584158B2 (en) * | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
| ES2791598T3 (es) | 2013-06-05 | 2020-11-05 | Bellicum Pharmaceuticals Inc | Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| BR112017007003A2 (pt) | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| CN118271463A (zh) | 2014-12-05 | 2024-07-02 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| WO2016127257A1 (en) | 2015-02-12 | 2016-08-18 | University Health Network | Chimeric antigen receptors |
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| US20180318303A1 (en) | 2015-04-15 | 2018-11-08 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| PL3368571T3 (pl) * | 2015-10-30 | 2023-05-02 | The Regents Of The University Of California | Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| CN106399255B (zh) | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| KR20230167769A (ko) | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| MA46862A (fr) | 2016-11-17 | 2019-09-25 | Bluebird Bio Inc | Convertisseur de signaux tgf béta |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| KR102879522B1 (ko) | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| EP3735460A4 (en) * | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| BR112020007542A2 (pt) * | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| US11738047B2 (en) | 2017-12-12 | 2023-08-29 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof |
| CN111819192A (zh) | 2018-03-02 | 2020-10-23 | 艾洛基治疗公司 | 可诱导的嵌合细胞激素受体 |
| EP3802578A4 (en) | 2018-06-01 | 2022-03-23 | Washington University | SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY |
| CA3102641A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| AU2020232216B2 (en) * | 2019-03-01 | 2025-09-25 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
| PE20211902A1 (es) | 2019-03-01 | 2021-09-27 | Allogene Therapeutics Inc | Receptores de citocinas quimericos constitutivamente activos |
-
2020
- 2020-08-28 US US17/005,757 patent/US12528856B2/en active Active
- 2020-08-28 CN CN202080061119.3A patent/CN114341193A/zh active Pending
- 2020-08-28 BR BR112022003553A patent/BR112022003553A2/pt unknown
- 2020-08-28 CA CA3145614A patent/CA3145614A1/en active Pending
- 2020-08-28 EP EP20772464.2A patent/EP4021582A1/en active Pending
- 2020-08-28 AU AU2020336131A patent/AU2020336131B2/en active Active
- 2020-08-28 JP JP2022505440A patent/JP2022545167A/ja active Pending
- 2020-08-28 MX MX2022002297A patent/MX2022002297A/es unknown
- 2020-08-28 WO PCT/US2020/048402 patent/WO2021041806A1/en not_active Ceased
- 2020-08-28 KR KR1020227004538A patent/KR20220052919A/ko active Pending
-
2022
- 2022-02-27 IL IL290960A patent/IL290960A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545167A5 (https=) | ||
| JP7179041B2 (ja) | 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用 | |
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP2022537824A5 (https=) | ||
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| JP2017504601A5 (https=) | ||
| JP2023552998A5 (https=) | ||
| JP2022512913A5 (https=) | ||
| CN110511912B (zh) | 免疫细胞的功能调节 | |
| JP2024510900A5 (https=) | ||
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| CN110616191A (zh) | 共刺激配体联合的car t疗法 | |
| CN111019905A (zh) | Car修饰细胞及其在制备自身免疫性疾病药物中的应用 | |
| EP4240381A1 (en) | Cells comprising t cell-antigen couplers and uses thereof | |
| JP2022525925A5 (https=) | ||
| CN111826353A (zh) | 调节t细胞功能和反应的方法 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| CN119661725A (zh) | Il5ra细胞表面标记物 | |
| WO2024011335A1 (zh) | 经修饰的免疫细胞 | |
| CN116209749A (zh) | 靶向mage-a4肽的细胞/基因疗法 | |
| HK40054580A (en) | Trifunctional t cell-antigen coupler and methods and uses thereof | |
| CN116103239A (zh) | 工程化免疫细胞及其用途 | |
| RU2018140063A (ru) | Композиции и способы для избирательной экспрессии белка | |
| HK1234091A1 (en) | Trifunctional t cell-antigen coupler and methods and uses thereof |